In patients with advanced NSCLC and PD-L1 expression on at least 50% of tumor cells, pembrolizumab was associated with significantly longer progression-free and overall survival...
In patients with previously untreated metastatic nonsquamous NSCLC without EGFR or ALK mutations, the addition of pembrolizumab to standard chemotherapy of pemetrexed and a plat...
A DELPHI consensus exercise was completed and an updated and improved SCARE Checklist is now presented.
Overall survival and objective response rates were significantly higher with nivolumab plus ipilimumab than with sunitinib among intermediate- and poor-risk patients with previo...
Abstract As obesity becomes a worldwide epidemic, its prevalence during reproductive age is also increased. Alarming reports state that two‐thirds of adults in the USA are overw...